GPT Healthcare Limited to Consider Q2 Results and Dividend

GPT Healthcare Limited will consider unaudited Q2 and H1 FY2027 results and a possible interim dividend at its 5 November 2026 board meeting. The decision matters because the company previously reported ₹120 crore in quarterly revenue, while net income fell 28% year-on-year to ₹10.6 crore in its cited second-quarter performance.

What will GPT Healthcare consider at its 5 November board meeting?

GPT Healthcare will consider and approve its unaudited financial results for the second quarter and half year ended 30 September 2026. The board will also review the limited review report issued by the company’s statutory auditors alongside the financial statements.

The agenda includes a decision on an interim dividend for FY2027, if any, on the company’s equity share capital. The notice does not specify a proposed dividend amount, record date or payment date. Those details would depend on a board approval and subsequent company disclosures.

The company issued the board-meeting intimation to BSE and also identified the same agenda in its exchange communication. This makes the meeting the scheduled event for investors seeking updated information on earnings, profitability and capital returns for the first half of FY2027.

Why are the earnings call and trading-window dates relevant?

GPT Healthcare has scheduled an earnings call for 6 November 2026 to discuss its Q2 and H1 FY2027 performance. The call follows the 5 November board meeting and is expected to provide management’s discussion of the financial results once they are approved and disclosed.

The company has also said its trading window will remain closed until 7 November 2026 under its code for prevention of insider trading. Such closures restrict trading by designated persons during periods when they may possess unpublished price-sensitive information, including quarterly results and dividend decisions.

The board meeting is therefore not only a financial reporting date but also a governance event governed by the company’s insider-trading controls. Investors will need to rely on the approved results, auditor review and any dividend announcement rather than assumptions ahead of the meeting.

What do GPT Healthcare's previously reported quarterly figures show?

GPT Healthcare’s cited second-quarter figures show revenue growth alongside lower profit. Revenue was ₹120 crore, up 14% from the corresponding quarter a year earlier, while net income was ₹10.6 crore, down 28% year-on-year. Earnings per share were ₹1.29, compared with ₹1.81 in the prior-year quarter.

The company also reported EBITDA of ₹22.74 crore in those results, marginally below ₹23.42 crore a year earlier. EBITDA margin was 19.13%, compared with 22.17% in the corresponding previous period. These figures show that revenue expansion did not translate into similar growth in profit during that reported quarter.

The forthcoming Q2 and H1 FY2027 release will provide the next reported measure of revenue, profitability and margin performance. Until the board publishes those results, the earlier figures remain historical reference points rather than evidence of the current quarter’s outcome.

How do hospital operations and dividends frame the announcement?

GPT Healthcare operates a chain of hospitals under the ILS Hospitals brand and is described as a regional corporate healthcare provider in Eastern India. The company operates 719 beds across five multispecialty hospitals, with an overall bed occupancy rate of 44.7% in the information provided.

Its expansion includes a 158-bed hospital in Raipur that was commissioned in May 2025. The company has stated a target of reaching 1,000 beds within the next two years, with a focus on Tier I and Tier II cities in Eastern India. It also reported that initial losses from the Raipur operations contributed to a 10% EBITDA decline in one cited reporting period.

Dividend history provides context for the upcoming decision, but does not establish the amount of any FY2027 interim payout. GPT Healthcare declared an interim dividend of ₹1 per share in November 2025 and a final dividend of ₹1.50 per share on 30 July 2026. The final dividend had a payment date of 4 September 2026 for shareholders who bought the stock before 30 July 2026.

Conclusion

GPT Healthcare’s 5 November meeting combines two material decisions: approval of unaudited Q2 and H1 FY2027 financial results and consideration of an interim dividend. The company’s previous quarterly disclosure showed 14% revenue growth to ₹120 crore but a 28% fall in net income to ₹10.6 crore, placing profitability and margins alongside revenue growth at the centre of investor attention.

The next confirmed event is the 6 November earnings call, following the board’s decision and results disclosure. Investors will watch for the approved Q2 and H1 figures, the statutory auditors’ limited review, any interim dividend amount and the company’s comments on hospital expansion, Raipur operations, occupancy and the stated 1,000-bed target.